Sobieszczyk Lab

Location and Contact Information

Hammer Lab

650 W 168th Street

William Black Building, BB-1017

New York, NY 10032

United States

Open location in Google Maps

Hammer Sciences Building

701 W.168 St, 11th Floor, ADARC 10th Floor

New York, NY 10032

United States

Principal Investigator

Magdalena E Sobieszczyk, MD, MPH
Associate Fellowship Program Director

Chief, Division of Infectious Diseases

Dr. Sobieszczyk’s major investigative interest is the treatment and prevention of HIV and SARS-CoV-2. The lab conducts investigator-initiated studies in HIV prevention, COVID-19, MPXV (monkeypox virus). Additionally, the Sobieszczyk Lab also provides research support infrastructure for clinical trials conducted under the auspices of the NIH-funded Clinical Research Networks: the COVID Prevention Network (CoVPN), HIV Vaccine Trials Network (HVTN), and AIDS Clinical Trials Group (ACTG).

Select Publications

Sobieszczyk ME, Maaske J, Falsey AR, Sproule S, Robb ML, Frenck RW Jr, Tieu HV, Mayer KH, Corey L, Neuzil KM, Tong T, Brewinski Isaacs M, Janes H, Bansal H, Edwards LM, Green JA, Kelly EJ, Shoemaker K, Takas T, White T, Bhuyan P, Villafana T, Hirsch AI; AstraZeneca AZD1222 Clinical Study Group. Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months. J Clin Invest. 2022 Sep 15;132(18):e160565. doi: 10.1172/JCI160565. PMID: 36106642; PMCID: PMC9479753.
Falsey AR**, Sobieszczyk ME**, Hirsch I, Sproule S, Robb ML, Corey L, Neuzil KM, Hahn W, Hunt J, Mulligan MJ, McEvoy C, DeJesus E, Hassman M, Little SJ, Pahud BA, Durbin A, Pickrell P, Daar ES, Bush L, Solis J, Carr QO, Oyedele T, Buchbinder S, Cowden J, Vargas SL, Guerreros Benavides A, Call R, Keefer MC, Kirkpatrick BD, Pullman J, Tong T, Brewinski Isaacs M, Benkeser D, Janes HE, Nason MC, Green JA, Kelly EJ, Maaske J, Mueller N, Shoemaker K, Takas T, Marshall RP, Pangalos MN, Villafana T, Gonzalez-Lopez A; AstraZeneca AZD1222 Clinical Study Group. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med. 2021 Dec 16;385(25):2348-2360. doi: 10.1056/NEJMoa2105290. Epub 2021 Sep 29. PMID: 34587382; PMCID: PMC8522798. (** contributed equally)
Sivapalasingam S, Lederer DJ, Bhore R, Hajizadeh N, Criner G, Hosain R, Mahmood A, Giannelou A, Somersan-Karakaya S, O'Brien MP, Boyapati A, Parrino J, Musser BJ, Labriola-Tompkins E, Ramesh D, Purcell LA, Gulabani D, Kampman W, Waldron A, Ng Gong M, Saggar S, Sperber SJ, Menon V, Stein DK, Sobieszczyk ME, Park W, Aberg JA, Brown SM, Kosmicki JA, Horowitz JE, Ferreira MA, Baras A, Kowal B, Thomas DiCioccio A, Akinlade B, Nivens MC, Braunstein N, Herman GA, Yancopoulos GD, Weinreich DM. Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial. Clin Infect Dis. 2022 Aug 24;75(1):e380-e388. doi: 10.1093/cid/ciac153. PMID: 35219277; PMCID: PMC8903479.
Weidmann MD, Berry GJ, Zucker JE, Huang S, Sobieszczyk ME, Green DA Bacterial Pneumonia and Respiratory Culture Utilization among Hospitalized Patients with and without COVID-19 in a New York City Hospital..J Clin Microbiol. 2022 Jul 20;60(7):e0017422. doi: 10.1128/jcm.00174-22. Epub 2022 Jun 1.PMID: 35642519
Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS, Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng Z, Huang Y, Ho DD. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021 Mar 8. doi: 10.1038/s41586-021-03398-2. Epub ahead of print. PMID: 33684923.
Teran RA, Sobieszczyk ME, Chiasson MA, Uhlemann AC, Weidler J, Shah JG, Chang JY, Otto C, Hirshfield S. Longitudinal Viral Load Monitoring Using Home-Collected Dried Blood Spot Specimens of MSM Living with HIV: Results from a Feasibility Pilot Study. AIDS Behav. 2021 Mar;25(3):661-666. doi: 10.1007/s10461-020-03030-w. PMID: 32909080; PMCID: PMC7480630.
Sobieszczyk, ME. Therapeutic HIV Vaccines and Broadly Neutralizing Antibodies. Top Antivir Med. 2020 Jan; 27(4): 97–101. PMCID: PMC7162678. PMID: 32224500
Hammer SM, Mofenson L, Havlir D, Vitorio M, Perriens J and the WHO Writing Committee: Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2003 version. World Health Organization, December 2003, available at www.who.int(link is external and opens in a new window).
Hammer SM. Clinical practice. Management of newly diagnosed HIV infection. N Engl J Med. 2005;353:1702-1710.
Sobieszczyk ME, Jones J, Wilkin T, Hammer SM. Advances in antiretroviral therapy. Top HIV Med. 2006;14:36-62.
Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society--USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. JAMA 2006;296:827-43.
Gripshover BM, Ribaudo H, Santana J, Gerber JG, Campbell TB, Hogg E, Jarocki B, Hammer SM, Kuritzkes DR; A5118 Team. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006;11:619-23.
Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society--USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med. 2006;14:827-43.
Hammer S, Riley A, Calmy A, Harries A, Duncombe C, Havlir D, Katabira E, Scano F, Malkin JE, Lange J, Mukerjee J, Currier J, Mofenson L, Harrington M, Schechter M, Kumarasamy N, Sow PS, Munderi P, Ojoo S, Cahn P, Phanuphak P, Eholie S, El Sadr W, Rodriguez W: Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach 2006 revision. World Health Organization, August 2006, available at www.who.int(link is external and opens in a new window).
Taylor BS, Sobieszczyk ME, McCutchan FE and Hammer SM: The challenge of HIV-1 subtype diversity. NEJM 2008;358:1590-1602.
Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM and Richman DD: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society - USA Panel. Clin Infect Dis 2008;47:266-285
Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JSG, Richman DD, Yeni PG and Volberding PA: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society – USA Panel. JAMA 2008; 300:555-570.
Demeter LM, DeGruttola V, Lustgarten S, Bettendorf D, Fischl M, Eshleman S, Spreen W, Nguyen BY, Koval CE, Eron JJ, Hammer S and Squires K: Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials 2008;9:11-25
View a Full List of Magdalena E Sobieszczyk's publications(link is external and opens in a new window)

Show more Publications

Sobieszczyk Lab

Location and Contact Information

Principal Investigator

Magdalena E Sobieszczyk, MD, MPH

Select Publications